Gut Robert sold $270K of QURE
Gut Robert sold 10,278 shares of uniQure N.V. (QURE) at an average of $26.32 ($26.03–$27.06, $0.27M total) across 4 trades over 2026-06-10 to 2026-06-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the director’s open-market sale size, timing window, and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Provides a fresh, primary-source datapoint on insider activity in QURE, but the 10b5-1 framing suggests limited incremental fundamental information.
What to watch
Traders may over-weight planned insider sales; without concurrent clinical/regulatory updates, the signal is usually weaker than discretionary selling.
Background
The article is an SEC Form 4 insider transaction filing for uniQure N.V. (QURE).
Ticker impact
uniQure director Gut Robert sold 10,278 shares in open-market transactions ($270,485 total) under a pre-arranged 10b5-1 plan.
Near-term impact likely limited; any reaction would be more about broader sentiment than this single planned sale.
The filing is a primary-source Form 4 showing a planned sale (10b5-1), with no accompanying fundamental catalyst (earnings, trial, deal, or regulatory action) in the text.
Market effects
No sector read-through provided; this is a single-company insider transaction disclosure.
None indicated; uniQure is the only subject.
None indicated; no cross-border deal/regulatory action mentioned.
Counterpoint
Because the sale is on a pre-arranged 10b5-1 schedule, it may reflect routine liquidity rather than bearish expectations.
Key entities
- insiderGut Robert
Director of uniQure N.V. who sold shares via open-market transactions under a 10b5-1 plan.
- issueruniQure N.V.
Company whose shares were sold; subject of the Form 4 disclosure.
